Journal: Experimental and Therapeutic Medicine

Article Title: miR-376c-3p modulates the properties of breast cancer stem cells by targeting RAB2A

doi: 10.3892/etm.2020.9196

Figure Lengend Snippet: Expression levels of miR-376c-3p and RAB2A in BCSCs. (A) Flow cytometry analysis of the proportion of CD44+CD24-cells. (B) Protein expression levels of stem cell markers OCT4 and SOX2 in MCF-7 cells and BCSCs. (C) Reverse transcription-quantitative PCR analysis of miR-376c-3p and RAB2A expression levels in MCF-10A cells, MCF-7 cells, non-BCSCs and BCSCs. (D) Protein expression levels of RAB2A in MCF-10A cells, MCF-7 cells, non-BCSCs and BCSCs. ** P<0.01 and *** P<0.001. miR, microRNA; RAB2A, Ras-related protein Rab-2A; BCSC, breast cancer stem cell; CD, cluster of differentiation; OCT4, octamer-binding transcription factor 4; SOX2, SRY-box transcription factor 2.

Article Snippet: CD44 + CD24 - cells were further sorted via fluorescence-activated cell sorting using anti-CD44 (cat. no. 75122; 1:100) and anti-CD24 (cat. no. 68390; 1:330) antibodies (each, Cell Signaling Technology, Inc.).

Techniques: Expressing, Flow Cytometry, Real-time Polymerase Chain Reaction, Binding Assay

Journal: Experimental and Therapeutic Medicine

Article Title: miR-376c-3p modulates the properties of breast cancer stem cells by targeting RAB2A

doi: 10.3892/etm.2020.9196

Figure Lengend Snippet: miR-376-3p reduces the stem cell population and downregulates stem cell regulatory proteins by targeting RAB2A. (A) Flow cytometry analysis of the proportion of CD44+CD24-cells. The effect of (B) miR-376c-3p mimic, pcDNA-RAB2A, (C) miR-376c-3p inhibitor and si-RAB2A on RAB2A, OCT4 and SOX2 expression levels. * P<0.05, ** P<0.01 and *** P<0.001. miR, microRNA; RAB2A, Ras-related protein Rab-2A; CD, cluster of differentiation; si, small interfering RNA; OCT4, octamer-binding transcription factor 4; SOX2, SRY-box transcription factor 2; NC, negative control.

Article Snippet: CD44 + CD24 - cells were further sorted via fluorescence-activated cell sorting using anti-CD44 (cat. no. 75122; 1:100) and anti-CD24 (cat. no. 68390; 1:330) antibodies (each, Cell Signaling Technology, Inc.).

Techniques: Flow Cytometry, Expressing, Small Interfering RNA, Binding Assay, Negative Control

Journal: Journal of Clinical Laboratory Analysis

Article Title: Correlation of integrin alpha 7 with clinicopathological characteristics and survival profiles, as well as its regulatory role in cell proliferation, apoptosis, and stemness in non‐small‐cell lung cancer

doi: 10.1002/jcla.22973

Figure Lengend Snippet: ITGA7 promoted cell proliferation, suppressed apoptosis, and enhanced stemness in A549 cells. A, ITGA7 mRNA expression after transfection. B, ITGA7 protein expression after transfection. C, Cell proliferation after transfection. D, E, Cell apoptosis after transfection. F, G, Proportion of CD133 + CD44 + cells after transfection. Comparison between two independent samples was determined by t test. P value < 0.05 was considered as significant. ITGA7, Integrin alpha 7

Article Snippet: Pre‐rinsed cells were, respectively, incubated with Alexa Fluor ® 647 conjugated CD133 Mouse mAb (Flow Specific) (1:50 dilution, CST) and FITC conjugated CD44 Rat mAb (1:100 dilution, CST) in incubation buffer at 37°C for an hour.

Techniques: Expressing, Transfection